OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

Main Article Content

Steven Dayan
Patricia Ogilvie
Alexander Z Rivkin
Steven G Yoelin
Julie K Garcia
Ilia L Ferrusi


Horizontal Frontalis Lines, Glabellar Lines, OnabotulinumtoxinA, Cosmetic, Randomized trial


Abstract Not Available


Disclosures: Study supported by Allergan.

Most read articles by the same author(s)